Neurogene Inc. (NGNE)
NASDAQ: NGNE
· Real-Time Price · USD
34.37
1.17 (3.52%)
At close: Oct 15, 2025, 3:59 PM
34.40
0.09%
After-hours: Oct 15, 2025, 06:00 PM EDT
3.52% (1D)
| Bid | 30.22 |
| Market Cap | 490.53M |
| Revenue (ttm) | -925K |
| Net Income (ttm) | -84.39M |
| EPS (ttm) | -4.31 |
| PE Ratio (ttm) | -7.97 |
| Forward PE | -5.35 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 34.95 |
| Volume | 118,863 |
| Avg. Volume (20D) | 161,150 |
| Open | 33.41 |
| Previous Close | 33.20 |
| Day's Range | 32.04 - 34.54 |
| 52-Week Range | 6.88 - 74.49 |
| Beta | 1.59 |
| Ex-Dividend Date | n/a |
About NGNE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NGNE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NGNE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 days ago
+22.18%
Neurogene shares are trading higher after the comp...
Unlock content with
Pro Subscription
3 months ago
+28.36%
Neurogene shares are trading higher after the company announced details of its registrational clinical trial designed to evaluate NGN-401 gene therapy for the treatment of females with Rett syndrome in participants ages 3 years and older.
